CLINICAL PHARMACOLOGY & THERAPEUTICS
Scope & Guideline
Transforming research into practice in clinical pharmacology.
Introduction
Aims and Scopes
- Pharmacokinetics and Pharmacodynamics:
Research articles often focus on the pharmacokinetic and pharmacodynamic modeling of drugs, including how various patient factors such as age, weight, and organ function influence drug behavior in the body. - Pharmacogenomics and Personalized Medicine:
The journal emphasizes the role of genetic factors in drug response, exploring how pharmacogenomic testing can guide personalized therapy and improve treatment outcomes. - Clinical Trials and Drug Development:
Publications frequently detail the design and outcomes of clinical trials, including innovative methodologies for trial design, ethical considerations, and regulatory implications. - Drug-Drug Interactions and Safety Assessments:
The impact of drug interactions on safety and efficacy is a critical area of focus, with studies evaluating the clinical significance of these interactions in diverse patient populations. - Real-World Evidence:
The journal promotes the use of real-world data to inform drug development and regulatory decision-making, providing insights into drug effectiveness and safety in everyday clinical practice. - Translational Research:
A consistent theme is the translation of preclinical findings into clinical applications, bridging the gap between laboratory research and patient care.
Trending and Emerging
- Artificial Intelligence and Machine Learning:
There is a growing trend towards the integration of AI and machine learning in drug development processes, predictive modeling, and personalized medicine, indicating a shift towards data-driven approaches in clinical pharmacology. - Real-World Data Utilization:
The use of real-world evidence is on the rise, with studies focusing on how real-world data can inform drug efficacy and safety, enhance clinical trial designs, and support regulatory decision-making. - Pharmacogenomics and Precision Dosing:
Research into pharmacogenomics is expanding, emphasizing the importance of genetic variability in drug metabolism and response, leading to more personalized and effective treatment regimens. - Innovations in Drug Delivery Systems:
Emerging studies are exploring novel drug delivery methods, including the use of biologics and advanced formulations that enhance therapeutic outcomes while minimizing side effects. - Focus on Rare Diseases:
An increasing number of publications are dedicated to the pharmacological management of rare diseases, reflecting a commitment to addressing unmet medical needs in this area. - Biologics and Biosimilars:
Research related to biologics, biosimilars, and their pharmacokinetic properties is trending, with an emphasis on safety, efficacy, and the implications for patient care.
Declining or Waning
- Traditional Pharmacology Models:
There is a noticeable decline in publications focused on traditional pharmacology models, as the field shifts towards more complex, systems-based approaches that incorporate pharmacogenomics and real-world evidence. - General Drug Class Studies:
Research examining broad classes of drugs without a specific focus on genetic or individual variabilities is becoming less common, with more emphasis now being placed on personalized medicine and targeted therapies. - Chronic Disease Management:
Topics related to general management strategies for chronic diseases are seeing reduced prominence, likely in favor of more innovative and tailored therapeutic approaches. - Preclinical Research:
There appears to be a waning interest in publishing preclinical studies that do not directly inform clinical applications, as the journal prioritizes translational research that connects laboratory findings to patient care.
Similar Journals
Clinical Pharmacology in Drug Development
Innovating therapeutics through rigorous research.Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.
Drug Discoveries and Therapeutics
Innovating therapeutics for transformative healthcare.Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.
BRITISH JOURNAL OF PHARMACOLOGY
Pioneering insights into drug mechanisms and therapeutic innovations.British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.
JOURNAL OF CLINICAL PHARMACOLOGY
Empowering Healthcare with Evidence-Based PharmacologyWelcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.
THERAPEUTIC DRUG MONITORING
Pioneering the Future of Therapeutic Drug ManagementTHERAPEUTIC DRUG MONITORING, published by Lippincott Williams & Wilkins, is a prestigious journal that focuses on the critical area of pharmacology, with a specific emphasis on the therapeutic optimization of drug therapy. With an ISSN of 0163-4356 and an E-ISSN of 1536-3694, this peer-reviewed journal has been contributing valuable research and insights to the field since its inception in 1979. As of 2023, it holds a Q2 classification in the Pharmacology category, indicating its prominent role in advancing pharmaceutical sciences. The journal aims to enhance understanding of drug effectiveness and safety through rigorous studies on drug monitoring and individualized therapy, making it an essential resource for researchers, healthcare professionals, and students dedicated to improving patient care. With its solid standing reflected in Scopus rankings, including a rank of #103 in medical pharmacology and a 62nd percentile, THERAPEUTIC DRUG MONITORING continues to be a vital publication for those aiming to contribute to and stay informed about the latest developments in the field.
ANTI-CANCER DRUGS
Empowering Researchers in the Fight Against CancerANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.
CTS-Clinical and Translational Science
Pioneering the path from lab to life in translational science.CTS-Clinical and Translational Science, published by WILEY, is a leading journal dedicated to advancing the fields of biochemistry, genetics, molecular biology, medicine, neuroscience, and pharmacology. With its Open Access policy since 2016, the journal ensures that groundbreaking research is readily available to a global audience, fostering collaboration and innovation. Based in the United Kingdom, CTS boasts a commendable Impact Factor that reflects its esteemed status, ranking in the Q1 category for various disciplines, including Pharmacology, Toxicology, and Pharmaceutics, and Biochemistry, Genetics and Molecular Biology. With its convergence years from 2008 to 2024, the journal remains at the forefront of scientific discovery, actively promoting novel research that bridges the gap between laboratory results and clinical application. Researchers, professionals, and students alike will find CTS an invaluable resource for the latest insights and advancements in clinical and translational science.
Expert Review of Clinical Pharmacology
Exploring the frontiers of pharmacology for enhanced clinical practice.Expert Review of Clinical Pharmacology, published by TAYLOR & FRANCIS LTD, is a leading peer-reviewed journal dedicated to the field of clinical pharmacology, with a strong focus on the development and application of pharmacological therapies in patient care. Boasting an impressive impact, the journal ranks in the first quartile across multiple categories including Medicine (miscellaneous), Pharmacology (medical), and Pharmacology, Toxicology and Pharmaceutics (miscellaneous), reflecting its influential position within the scientific community. With a Scopus ranking of #6 in General Pharmacology, Toxicology and Pharmaceutics, the journal also achieves a commendable 93rd percentile, further emphasizing its importance as a resource for researchers and clinicians alike. As it continues to publish innovative reviews and research articles from 2008 until 2024, the Expert Review of Clinical Pharmacology plays an essential role in advancing knowledge, improving clinical practice, and fostering collaboration among experts in pharmacology, thereby driving forward the field's evolution towards better patient outcomes.
Expert Opinion on Drug Metabolism & Toxicology
Innovative Perspectives on Drug Metabolism and ToxicologyExpert Opinion on Drug Metabolism & Toxicology, published by Taylor & Francis Ltd, is a leading journal in the fields of pharmacology and toxicology, with a distinguished reputation gleaned from its Q1 rankings in both disciplines as of 2023. With an ISSN of 1742-5255 and an E-ISSN of 1744-7607, this journal aims to foster innovative discussions and critical insights into the metabolism and toxicological assessment of drugs, appealing to a wide audience of researchers, professionals, and students. The journal's commitment to maintaining high academic standards is reflected in its placement within the top quartiles of the Scopus rankings—ranked 17th in Toxicology and 73rd in Pharmacology—demonstrating its significant impact and relevance in advancing knowledge within the drug development sector. Published since 2005 and converging into 2024, it provides a platform for timely dissemination of expert opinions, systematic reviews, and original research, reinforcing its vital role in shaping the future of pharmacological sciences in an ever-evolving landscape.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Fostering Knowledge in Pharmacological AdvancementsExpert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.